
    
      2-part study. Part A in psychedelic-na√Øve healthy volunteers. Part B in patients with MDD who
      score moderate-severe on Ham-D.

      Healthy volunteers will receive a single dose of SPL026 in a dose-escalation parallel group
      study.

      Patients will receive up to 2 single doses of SPL026, 2 weeks apart. Dose 1 will be
      randomised double-blind with placebo. Dose 2 will be open label, active SPL026.

      SPL026 will be administered by IV injection. Safety and tolerability, PK, PD and efficacy
      will be measured.
    
  